Wuxi High-tech Zone Venture Capital Holding Group
Overview
Wuxi High-tech Zone Venture Capital Holding Group is a Chinese investment firm specializing in venture capital investments, asset management, and entrepreneurial management services.
Portfolio Companies
2
Website
wxfig.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ETERN Therapeutics | Apr 2024 | Series B Extension | Co-investor |
| Shanghai Realbio Technology Co., Ltd. | Apr 2019 | Series A Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Wuxi High-tech Zone Venture Capital Holding Group based?
Wuxi High-tech Zone Venture Capital Holding Group is headquartered in Wuxi, China.
When was Wuxi High-tech Zone Venture Capital Holding Group founded?
Founding year information for Wuxi High-tech Zone Venture Capital Holding Group is not publicly available.
How many portfolio companies does Wuxi High-tech Zone Venture Capital Holding Group have?
Wuxi High-tech Zone Venture Capital Holding Group has 2 portfolio companies in Caplight's dataset.
What are some companies in Wuxi High-tech Zone Venture Capital Holding Group's portfolio?
Portfolio companies visible on Caplight include ETERN Therapeutics, Shanghai Realbio Technology Co., Ltd..
What was Wuxi High-tech Zone Venture Capital Holding Group's most recent investment shown here?
Wuxi High-tech Zone Venture Capital Holding Group's most recent investment in this portfolio sample was in ETERN Therapeutics in 2024.
What sectors does Wuxi High-tech Zone Venture Capital Holding Group focus on?
Wuxi High-tech Zone Venture Capital Holding Group focuses on Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Wuxi High-tech Zone Venture Capital Holding Group focus on?
Wuxi High-tech Zone Venture Capital Holding Group typically invests at the Early stage.
What is Wuxi High-tech Zone Venture Capital Holding Group's AUM?
Wuxi High-tech Zone Venture Capital Holding Group's assets under management are estimated at over $1.2B.